Filing a claim for cancer caused by contaminated medication starts with one critical step most people get wrong: understanding that these cases are almost never true class actions. If you were diagnosed with cancer after taking a drug contaminated with NDMA — a probable carcinogen found in medications like Zantac, valsartan, and metformin — your cancer claim is filed as an individual personal injury lawsuit, typically consolidated into a multidistrict litigation. The distinction matters because individual claims allow for personalized compensation based on your specific diagnosis, treatment, and suffering, rather than a one-size-fits-all payout split among thousands.
In October 2025, GSK reached a $2.2 billion settlement covering approximately 80,000 plaintiffs in the Zantac litigation, illustrating both the scale and the individual nature of these cases. The process itself involves gathering your medical records and proof of drug usage, consulting a mass tort attorney who works on contingency, and filing before your state’s statute of limitations expires. But the details beneath each of those steps are where cases succeed or fall apart. This article walks through the specific medications under litigation, who qualifies, the documentation you need, how the legal process actually works, what the FDA’s safety thresholds mean for your case, and what recent settlements tell us about where contaminated medication lawsuits are heading.
Table of Contents
- What Medications Have Caused Cancer Claims and How Are Lawsuits Filed?
- Who Qualifies to File a Contaminated Medication Cancer Claim?
- What Documentation Do You Need to Build a Strong Case?
- How Does the Legal Process Work — Individual Claims vs. Class Actions?
- Statutes of Limitations and Common Filing Mistakes
- How the FDA’s NDMA Safety Threshold Affects Your Case
- Where Contaminated Medication Litigation Is Heading
- Frequently Asked Questions
What Medications Have Caused Cancer Claims and How Are Lawsuits Filed?
The largest wave of contaminated medication litigation centers on drugs found to contain NDMA, or N-Nitrosodimethylamine, which the International Agency for Research on Cancer classifies as a Group 2A carcinogen — meaning it is probably carcinogenic to humans. The FDA and Health Canada set the acceptable daily intake limit for NDMA at just 0.096 micrograms per day. When medications exceed that threshold over long periods, the cancer risk becomes significant enough to support legal claims. The FDA requested all ranitidine products, sold under the brand name Zantac, be withdrawn from the market after discovering NDMA forms as the drug breaks down, even under normal storage conditions. That withdrawal triggered a litigation wave that, as of late 2025, still includes 1,812 active federal lawsuits. Zantac is not the only drug involved.
Valsartan, a blood pressure medication, had batches contaminated with NDMA, and more than 1,200 lawsuits are now consolidated in multidistrict litigation in New Jersey federal court. Other recalled drugs with NDMA contamination include metformin, losartan, irbesartan, varenicline (sold as Chantix), rifampin, and rifapentine. As recently as October 7, 2025, the FDA recalled more than 580,000 prazosin capsules over nitrosamine contamination. The breadth of affected medications means that even people who never took Zantac may have grounds for a claim if they developed cancer after extended use of another NDMA-contaminated drug. The lawsuits are filed as individual personal injury claims, not class actions in the traditional sense. A class action might cover everyone who purchased a contaminated drug and wants a refund, but cancer claims require individualized proof of diagnosis, drug exposure, and damages. These individual cases get grouped into an MDL for efficiency during pretrial proceedings — shared discovery, coordinated motions, bellwether trials — but each plaintiff retains their own case with their own potential settlement or verdict.
Who Qualifies to File a Contaminated Medication Cancer Claim?
Eligibility requirements are more specific than most people expect, and failing to meet even one criterion can disqualify your claim entirely. Using the Zantac litigation as an example — since it is the most developed of the NDMA cases — plaintiffs must demonstrate that they used the medication regularly for at least one year during the relevant time period. Casual or short-term use generally does not meet the threshold. You must also have been diagnosed with an eligible cancer type, which includes bladder, stomach, esophageal, liver, pancreatic, breast, kidney, or colorectal cancer. Not every cancer qualifies, and the list of eligible diagnoses has been a point of significant legal debate. Timing also matters. The cancer diagnosis must have occurred within 20 years of last use and before the claimant reached age 89.
These cutoffs exist because establishing causation becomes increasingly difficult with longer gaps between exposure and diagnosis, and because background cancer rates rise substantially with age, making it harder to attribute the cancer to the medication rather than to aging itself. However, if you were diagnosed outside these windows, it does not necessarily mean you have no legal options — it means the standard MDL framework may not apply, and you would need to discuss alternative theories of liability with an attorney. There are also disqualifying conditions that can undermine a claim. Pre-existing hepatitis B, hepatitis C, H. pylori infections, or achalasia may disqualify you because these conditions independently elevate cancer risk for several of the same cancer types associated with NDMA exposure. Defense attorneys will argue that your cancer was caused by the pre-existing condition rather than the medication. This does not mean your case is automatically dead, but it does create a significant hurdle that your legal team would need to address with expert medical testimony.
What Documentation Do You Need to Build a Strong Case?
The strength of a contaminated medication cancer case lives or dies on documentation. You need to establish two things with evidence: that you took the medication for a sustained period and that you were subsequently diagnosed with a qualifying cancer. The most direct proof of drug usage includes prescription records from your doctor, pharmacy purchase records, and insurance claims showing the medication was dispensed to you. If those records are unavailable — pharmacies may not retain records beyond a certain number of years — a signed declaration from your prescribing physician confirming that they prescribed the medication can serve as supporting evidence. For the cancer diagnosis, you will need pathology reports, oncology records, treatment records, and imaging studies. The more thoroughly documented your diagnosis, the stronger the causal link your attorneys can argue.
For example, in the Zantac litigation, plaintiffs who could produce continuous prescription records spanning several years alongside a clear cancer diagnosis within the eligible timeframe were in a substantially stronger position than those relying on memory alone. Some firms, like Seeger Weiss and others handling mass tort pharmaceutical cases, have intake teams specifically designed to help locate and compile these records, often through medical record retrieval services. One detail that trips people up: you do not need to prove that NDMA definitively caused your specific cancer. The legal standard in civil litigation is preponderance of the evidence — meaning it is more likely than not. Expert witnesses, epidemiological studies, and the FDA’s own findings about NDMA contamination levels form the backbone of that argument. Your job as a plaintiff is to prove you took the drug and developed cancer. Your attorneys and their experts handle the causation science.
How Does the Legal Process Work — Individual Claims vs. Class Actions?
The difference between a class action and a multidistrict litigation is not just legal jargon — it directly affects your compensation. In a true class action, one or a few named plaintiffs represent an entire class, and any settlement or verdict is divided among all class members, often resulting in modest individual payouts. For contaminated medication cases involving cancer, the damages are too varied and too significant for that structure. Someone diagnosed with stage IV pancreatic cancer has a fundamentally different claim than someone with an early-stage bladder cancer that was caught and treated. Individual lawsuits within an MDL allow each plaintiff’s case to be valued based on their specific circumstances. That said, there is a class action component to some of these litigations, and the distinction matters. Anyone who purchased a contaminated drug — whether they developed cancer or not — may be eligible for a consumer refund class action. These are separate from the personal injury claims and typically result in much smaller payouts, often just the cost of the medication.
The cancer claims, filed individually, carry far higher potential compensation. In the Zantac litigation, the $2.2 billion GSK settlement divided among roughly 80,000 plaintiffs averages out to approximately $27,500 per plaintiff, though actual amounts vary enormously based on cancer type, severity, and strength of evidence. Some individual verdicts and settlements in pharmaceutical cancer cases have reached into the millions — a Baltimore jury awarded $1.5 billion to a single plaintiff in the Johnson & Johnson talcum powder litigation. The tradeoff is time. MDL cases move slowly. Pretrial proceedings, bellwether trials, and settlement negotiations can stretch over years. The valsartan MDL has been consolidated in New Jersey federal court with over 1,200 cases and is still working through discovery. If you need compensation quickly, some firms offer litigation financing or can help identify interim assistance programs, but the legal process itself does not move fast.
Statutes of Limitations and Common Filing Mistakes
The single most common reason people lose the right to file a contaminated medication cancer claim is missing their state’s statute of limitations. This deadline varies by state and is typically calculated from the date you were diagnosed with cancer — or from the date you knew or should have known the cancer was linked to the medication. In some states, you may have as little as one year from diagnosis. In others, you may have three or four years. A handful of states apply a discovery rule that can extend the deadline if you could not reasonably have known about the contamination, but you cannot count on this. The mistake people make is assuming they have plenty of time. By the time media coverage reaches them, by the time they connect their diagnosis to a recalled drug, months or years may have already passed.
If you suspect your cancer may be linked to a contaminated medication, consult an attorney immediately, even if you are still gathering records. Most mass tort attorneys offer free initial consultations and work on contingency, meaning they collect no fees unless you win. The consultation itself can clarify whether you are still within your filing window and whether your case has merit. Another common error is filing in the wrong jurisdiction or attempting to handle the claim without experienced counsel. Pharmaceutical mass tort litigation involves complex science, coordinated multidistrict proceedings, and defense teams funded by companies with billions at stake. GSK, the manufacturer of Zantac, is one example — they fought the litigation aggressively before agreeing to the $2.2 billion settlement. Attempting to navigate this without an attorney experienced in pharmaceutical or mass tort law is not recommended.
How the FDA’s NDMA Safety Threshold Affects Your Case
The FDA’s established acceptable daily intake limit for NDMA — 0.096 micrograms per day — serves as a benchmark in litigation, but it is not a bright line that automatically wins or loses a case. Plaintiffs’ attorneys argue that contaminated medications exposed patients to NDMA levels far exceeding this threshold, sometimes by orders of magnitude, over sustained periods. Defense attorneys counter that the threshold itself includes substantial safety margins, and that occasional exposure above the limit does not necessarily cause cancer. The science is contested, and both sides bring expert witnesses to argue their interpretation.
What strengthened plaintiffs’ cases in the Zantac litigation was the FDA’s own decision to request withdrawal of all ranitidine products from the market. When a regulatory agency takes that step, it is powerful evidence that the contamination posed a genuine safety risk. Similarly, the October 2025 recall of over 580,000 prazosin capsules over nitrosamine contamination reinforces the argument that NDMA in medications is not a theoretical concern but an ongoing safety failure. A University of Connecticut analysis following that recall suggested the problem may point to higher safety risks in older generic drugs, where manufacturing oversight may be less rigorous.
Where Contaminated Medication Litigation Is Heading
The landscape of contaminated medication lawsuits continues to expand. Beyond Zantac and valsartan, new litigation is emerging around other drugs with contamination or safety concerns. In 2026, new lawsuits allege that Dupixent, a widely prescribed medication for eczema and asthma, increases the risk of cutaneous T-cell lymphoma without adequate warnings on its label. Meanwhile, the proposed $7.25 billion Roundup class settlement — covering claims that the herbicide causes non-Hodgkin lymphoma — is facing legal pushback from 14 law firms representing approximately 20,000 plaintiffs who argue the settlement timeline is too compressed.
These developments suggest that pharmaceutical and chemical exposure litigation is not slowing down. For individuals who took NDMA-contaminated medications and were later diagnosed with cancer, the window to file remains open in many cases, but it will not stay open indefinitely. Statutes of limitations continue to run, and as settlements are reached and MDLs wind down, the opportunity to join existing litigation narrows. If you have been putting off looking into whether you qualify, the practical advice is straightforward: gather your records, contact a mass tort attorney for a free evaluation, and find out where you stand before the deadlines pass.
Frequently Asked Questions
Is a contaminated medication cancer lawsuit the same as a class action?
No. Cancer claims are filed as individual personal injury lawsuits, typically consolidated into a multidistrict litigation for efficiency. Class actions related to contaminated medications usually cover consumer refunds for the purchase price, not cancer compensation. Individual claims allow for personalized damages based on your specific diagnosis and circumstances.
How long do I have to file a claim for cancer caused by contaminated medication?
The statute of limitations varies by state and is generally calculated from the date of your cancer diagnosis or from when you discovered the link between your cancer and the medication. Deadlines can range from one to four years depending on jurisdiction. Consult an attorney as soon as possible to determine your specific deadline.
What types of cancer qualify for a contaminated medication lawsuit?
In the Zantac litigation, eligible cancers include bladder, stomach, esophageal, liver, pancreatic, breast, kidney, and colorectal cancer. The qualifying cancer types may differ depending on which medication is involved. Not every cancer diagnosis will meet the eligibility criteria.
Do I need to pay upfront to hire a lawyer for a contaminated medication case?
Most mass tort attorneys handle these cases on contingency, meaning they charge no upfront fees and only collect payment if you receive a settlement or verdict. Initial consultations are typically free.
Can I still file a claim if I no longer have my prescription records?
Yes, though it makes the case more challenging. Pharmacy databases, insurance records, and physician declarations can sometimes substitute for missing prescription records. An experienced attorney can help identify alternative sources of documentation.
You Might Also Like
- Can You File a Class Action for Dangerous Side Effects of Medication
- How to Join a Class Action Lawsuit for Contaminated IV Saline
- How to File a Class Action for Defective Surgical Mesh